NCT Number: NCT00243113
Docetaxel and Radiation Therapy in Treating Patients With Stage II or Stage III Cancer of the Larynx or Hypopharynx
RATIONALE: Drugs used in chemotherapy, such as docetaxel work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving docetaxel together with radiation therapy may kill more tumor cells.
PURPOSE: This phase II trial is studying how well giving docetaxel together with radiation therapy works in treating patients with stage II or stage III cancer of the larynx or hypopharynx.
Looking for future studies?
Notify MeKey information
Conditions
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 2
Primary location
Aichi Cancer Center, Nagoya, Aichi-ken, Japan
About this study
OBJECTIVES:
Primary
- Determine the objective response of the primary tumor in patients with stage II or III squamous cell carcinoma of the larynx or hypopharynx treated with docetaxel and radiotherapy.
Secondary
- Determine the local relapse-free survival of patients treated with this regimen.
- Determine the larynx-preservation survival of patients treated with this regimen.
- Determine the overall survival of patients treated with this regimen.
- Determine the protocol completion rate in patients treated with this regimen.
- Determine the adverse effects of this regimen in these patients.
OUTLINE: This is a multicenter study.
Patients receive docetaxel IV over 1 hour on days 1, 8, 15, 22, and 29 and undergo radiotherapy on days 1-5, 8-12, 15-19, 22-26, and 29-33.
PROJECTED ACCRUAL: A total of 25-50 patients will be accrued for this study.
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
DISEASE CHARACTERISTICS:
- Histologically confirmed squamous cell carcinoma of the larynx or hypopharynx
- Stage II or III disease
- Solitary lymph node metastasis located in level II-III allowed
- Age 70 and over OR meets 1 of the following criteria:
- Creatinine clearance 30-60 mL/min
- History of platinum allergy
- Diagnosis of unstable angina
- Ineligible for systemic chemotherapy, including high-dose platinum-containing regimens
PATIENT CHARACTERISTICS:
Age
- See Disease Characteristics
Performance status
- ECOG 0-2
Life expectancy
- Not specified
Hematopoietic
- WBC > 3,000/mm^3
- Neutrophil count > 1,500/mm^3
- Hemoglobin > 10 g/dL
- Platelet count > 100,000/mm^3
Hepatic
- AST and ALT ≤ 2.0 times upper limit of normal
- Bilirubin < 2.0 mg/dL
- No severe liver disease
Renal
- See Disease Characteristics
- Creatinine clearance ≥ 30 mL/min
- No severe renal disease
Pulmonary
- No severe pulmonary disease
Other
- No severe neurologic disease
PRIOR CONCURRENT THERAPY:
Biologic therapy
- Not specified
Chemotherapy
- No prior systemic chemotherapy
Endocrine therapy
- Not specified
Radiotherapy
- No prior radiotherapy
Surgery
- No prior surgery
Treatment and study plan
radiation therapy
RadiationPrimary outcomes
-
Objective response of primary tumor
Secondary outcomes
-
Local complete response rate
-
Local progression-free survival at 2 years
-
Local relapse-free survival
-
Larynx preservation survival at 2 years
-
Overall survival at 2 years
-
Treatment completion rate
-
Incidence of adverse effects
Sponsors and collaborators
Lead sponsor
Aichi Cancer Center
Other
Registry information
Official study title
Multi-Institutional Phase II Study of Weekly Docetaxel and Concurrent Radiotherapy for Laryngeal and Hypopharyngeal Cancer in the Group of Elderly and/or Patients With Medical Illness
Important dates
- Study start
- 2004
- Primary completion
- 2008
- Study completion
- 2008
- First posted
- Oct 21, 2005
- Registry last updated
- Mar 26, 2013
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
OSI-774/Cisplatin/Taxotere in Head & Neck Squamous Cell Cancer
NCT00076310
Carcinoma, Carcinoma, Squamous Cell
Houston, Texas, United States
View Trial DetailsRadiation Therapy With Cisplatin or Cetuximab in Treating Patients With Oropharyngeal Cancer
NCT01302834
Carcinoma, Carcinoma, Squamous Cell
Anchorage, Alaska, United States
View Trial DetailsPhase I Study of Olaparib Combined With Cisplatin-based Chemoradiotherapy to Treat Locally Advanced Head and Neck Cancer
NCT02308072
Carcinoma, Carcinoma, Squamous Cell
London, United Kingdom
View Trial DetailsStudy of MEDI0562 Prior to Surgical Resection in Head and Neck Squamous Cell Carcinoma (HNSCC) or Melanoma
NCT03336606
Carcinoma, Carcinoma, Squamous Cell
Portland, Oregon, United States
View Trial Details